Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies.

P, Mitchell; I, McAllister; M, Larsen; G, Staurenghi; JF, Korobelnik; DS, Boyer; DV, Do; DM, Brown; TA, Katz; A, Berliner; R, Vitti; O, Zeitz; C, Metzig; C, Lu; FG, Holz

doi:10.1016/j.oret.2018.02.011

Public

Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies.

Shared by NobleBlocks on Mar 31, 2018 • 12:00 AM UTC

Authors:

Mitchell P

McAllister I

Larsen M

Abstract

Purpose To evaluate the impact of intravitreal aflibercept (EYLEA, Regeneron Pharmaceuticals, Tarrytown, NY) versus laser on progression of diabetic retinopathy (DR) severity in Intravitreal Aflibercept Injection in Vision Impairment due to DME (VIVID-DME) and Study of Intravitreal Aflibercept Injec...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!